Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $877.11 | 10 | 96.3% |
| Education | $33.38 | 2 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $254.29 | 3 | $0 (2022) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $126.18 | 1 | $0 (2024) |
| Allergan Inc. | $125.51 | 2 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $123.77 | 1 | $0 (2017) |
| Neurocrine Biosciences, Inc. | $94.00 | 1 | $0 (2018) |
| Shire North American Group Inc | $81.72 | 1 | $0 (2018) |
| Eisai Inc. | $71.64 | 1 | $0 (2021) |
| Axsome Therapeutics, Inc. | $33.38 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $126.18 | 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($126.18) |
| 2023 | $33.38 | 2 | Axsome Therapeutics, Inc. ($33.38) |
| 2022 | $254.29 | 3 | ABBVIE INC. ($254.29) |
| 2021 | $71.64 | 1 | Eisai Inc. ($71.64) |
| 2019 | $125.51 | 2 | Allergan Inc. ($125.51) |
| 2018 | $175.72 | 2 | Neurocrine Biosciences, Inc. ($94.00) |
| 2017 | $123.77 | 1 | Sunovion Pharmaceuticals Inc. ($123.77) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/01/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $126.18 | General |
| Category: PSYCHIATRY | ||||||
| 11/03/2023 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $16.69 | General |
| Category: Neurology | ||||||
| 11/02/2023 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $16.69 | General |
| Category: Neurology | ||||||
| 12/05/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $124.96 | General |
| Category: NEUROSCIENCE | ||||||
| 07/27/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $122.33 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/02/2021 | Eisai Inc. | Dayvigo (Drug) | Food and Beverage | Cash or cash equivalent | $71.64 | General |
| Category: Neurology | ||||||
| 11/05/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $113.52 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2018 | Shire North American Group Inc | MYDAYIS (Drug) | Food and Beverage | In-kind items and services | $81.72 | General |
| Category: NEUROSCIENCE | ||||||
| 02/07/2018 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $94.00 | General |
| Category: NEUROLOGY | ||||||
| 04/04/2017 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $123.77 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 68 | 199 | $35,560 | $13,232 |
| 2022 | 4 | 98 | 260 | $46,431 | $17,937 |
| 2021 | 4 | 97 | 295 | $52,527 | $19,621 |
| 2020 | 5 | 118 | 311 | $58,377 | $20,966 |
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 89 | $19,313 | $7,223 | 37.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 24 | 89 | $11,837 | $4,144 | 35.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 21 | $4,410 | $1,865 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 106 | $23,002 | $9,238 | 40.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 27 | 109 | $14,497 | $5,480 | 37.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 31 | $6,510 | $2,347 | 36.1% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Facility | 2022 | 14 | 14 | $2,422 | $871.57 | 36.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 28 | 124 | $26,908 | $10,078 | 37.5% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 28 | 125 | $16,625 | $6,167 | 37.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 28 | $5,880 | $2,239 | 38.1% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Facility | 2021 | 16 | 18 | $3,114 | $1,136 | 36.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 119 | $25,823 | $8,114 | 31.4% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 25 | 119 | $15,827 | $6,356 | 40.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 40 | $8,400 | $3,294 | 39.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $4,521 | $1,754 | 38.8% |
| 90836 | Psychotherapy, 45 minutes | Facility | 2020 | 20 | 22 | $3,806 | $1,449 | 38.1% |
About Dr. Marc Davis, MD
Dr. Marc Davis, MD is a Psychiatry healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427161447.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Davis, MD has received a total of $910.49 in payments from pharmaceutical and medical device companies, with $126.18 received in 2024. These payments were reported across 12 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($877.11).
As a Medicare-enrolled provider, Davis has provided services to 381 Medicare beneficiaries, totaling 1,065 services with total Medicare billing of $71,756. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Location Salt Lake City, UT
- Active Since 08/16/2006
- Last Updated 08/07/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1427161447
Products in Payments
- VRAYLAR (Drug) $379.80
- CAPLYTA (Drug) $126.18
- LATUDA (Drug) $123.77
- INGREZZA (Drug) $94.00
- MYDAYIS (Drug) $81.72
- Dayvigo (Drug) $71.64
- Sunosi (Drug) $33.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Salt Lake City
Noel Gardner, Md, MD
Psychiatry — Payments: $734,576
Dr. Clark Johnson, M.d, M.D
Psychiatry — Payments: $8,896
Dr. Mark Neuman, Md, MD
Psychiatry — Payments: $2,188
Julian Thorne, Md, MD
Psychiatry — Payments: $2,152
Mithu Chaudhury, Do, DO
Psychiatry — Payments: $1,229
Dr. Sajid Faizi, M.d, M.D
Psychiatry — Payments: $882.96